“Pancreas-sparing duodenectomy, although technically demanding, eliminates the need for pancreatic resection. Pancreas-sparing duodenectomy is associated with good absorptive capacity, weight gain, and quality of life. Furthermore, it may reduce the risk of subsequent malignancy. Long-term surveillance, however, is still required. Pancreas-sparing duodenectomy is contraindicated in the setting of malignancy.”

“it is important to keep in mind the recent developments in the preventive therapy of polyp formation. Cyclooxygenase inhibitors have been tested in the laboratory with promising results. The rationale for this therapy is to counteract the effect of prostaglandins, which
are believed to promote tumorigenesis by increasing cellular proliferation and inhibition of apoptosis.12 Following the initial experience with sulindac that showed a moderate response in both formation and growth of polyps in patients with FAP, a new class of drugs has been recently described that selectively inhibits the inducible form of the cyclooxygenase 2.”

Sarmiento JM, et al. Pancreas-sparing duodenectomy for duodenal polyposis. Arch Surg. 2002 May;137(5):557-62; discussion 562-3. doi: 10.1001/archsurg.137.5.557. PMID: 11982469.